What is the optimal treatment of stage IIIA–N2 non-small-cell lung cancer after EORTC 08941?

References

• Mountain CF. The international system for staging lung cancer. Chest111, 1710–1717 (1997).
   PubMed Web of Science ®Google Scholar
• Andre F, Grunenwald D, Pignon JP et al. Survival of patients with resected N2 non-small cell lung cancer: evidence for a subclassification and implications. J. Clin. Oncol.18, 2981–2989 (2000).
   PubMed Web of Science ®Google Scholar
• NSCLC Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br. Med. J.311, 899–909 (1995).
   PubMedGoogle Scholar
• Eberhardt WE, Albain KS, Pass H et al. Induction treatment before surgery for non-small cell lung cancer. Lung Cancer42(Suppl. 1), S9–S14 (2003).
   PubMedGoogle Scholar
• Farray D, Mirkovic N, Albain KS. Multimodality therapy for stage III non-small-cell lung cancer. J. Clin. Oncol.23, 3257–3269 (2005).
   PubMed Web of Science ®Google Scholar
• van Meerbeeck JP, Kramer GWPM, Van Schil PEY et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA–N2 non-small-cell lung cancer. J. Natl Cancer Inst.99, 442–450 (2007).
   PubMedGoogle Scholar
• Albain KS, Swann RS, Rusch V et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) and CT/RT followed by surgical resection for stage IIIA (pN2) non-small cell lung cancer: outcomes update on North American Intergroup 0139.J. Clin. Oncol.23(Suppl. 16), 624 (2005).
   Google Scholar
• Rosell R, Gumez-Codina J, Camps C et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessement of a randomized controlled trial. Lung Cancer26, 7–14 (1999).
   PubMed Web of Science ®Google Scholar
• Roth JA, Atkinson EN, Fossella T et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer21, 1–6 (1998).
   PubMed Web of Science ®Google Scholar
• Van Schil P, Van Meerbeeck J, Kramer G et al. Morbidity and mortality in the surgery arm of the EORTC 08941 trial. Eur. Resp. J.26, 192–197 (2005).
   PubMed Web of Science ®Google Scholar
• Van Meerbeeck JP, Kramer G, Legrand C et al. on behalf of the EORTC-Lung Cancer Group (LCG). Does downstaging in patients (pts) with III A–N2 non-small cell lung cancer (NSCLC) and a response to induction chemotherapy (ICT) influence outcome with surgery (S) or radiotherapy (RT)? An exploratory analysis of EORTC 08941.J. Clin. Oncol.24(Suppl. 18), 7047 (2006).
   Google Scholar
• Robinson LA, Ruckdeschel JC, Wagner H, Stevens CW. Treatment of non-small cell lung cancer – stage IIIA: ACCP evidence-based clinical practice guidelines (2nd Edition). Chest132, 243–265 (2007).
   Google Scholar
• Betticher D, Schmitz SH, Tötsch M et al. Mediastinal lymph node clearance after docetaxel–cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pn2 non-small-cell lung cancer: a multicenter Phase II trial. J. Clin. Oncol.21, 1752–1759 (2003).
   PubMed Web of Science ®Google Scholar
• Lorent N, De Leyn P, Lievens Y et al. Long-term survival of surgically staged IIIA–N2 non-small-cell lung cancer treated with surgical combined modality approach: analysis of a 7-year prospective experience. Ann. Oncol.15, 1645–1653 (2004).
   PubMed Web of Science ®Google Scholar
• El Sharouni SY, Kal HB, Battermann JJ. Accelerated regrowth of non-small-cell lung tumours after induction chemotherapy. Br. J. Cancer89, 2184–2189 (2003).
   PubMed Web of Science ®Google Scholar
• Treasure T, Utley M. Ten traps for the unwary in surgical series: a case study in mesothelioma reports. J. Thorac. Cardiovasc. Surg.133, 1414–1418 (2007).
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Betticher D, Eberhardt W, De Leyn P. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA–N2 non-small cell lung cancer. J. Thorac. Oncol.2, 684–685 (2007).
   PubMedGoogle Scholar
• Vergeer MR, Doornaert P, Leemans CR et al. Control of nodal metastases in squamous cell head and neck cancer treated by radiation therapy or chemoradiation. Radiother. Oncol.79, 39–44 (2006).
   PubMedGoogle Scholar
• Rusch VW, Giroux DJ, Kraut MJ et al. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J. Clin. Oncol.25, 313–318 (2007).
   PubMed Web of Science ®Google Scholar
• Cerfolio RJ, Bryant AS, Ojha B. Restaging patients with N2 (stage IIIa) nonsmall cell lung cancer after neoadjuvant chemoradiotherapy: a prospective study. J. Thorac. Cardiovasc. Surg.131, 1229–1235 (2006).
   PubMed Web of Science ®Google Scholar
• De Leyn P, Stroobants S, De Wever W et al. Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA–N2 non-small-cell lung cancer: a Leuven Lung Cancer Group study. J. Clin. Oncol.24, 3333–3339 (2006).
   PubMed Web of Science ®Google Scholar
• Annema JT, Versteegh MI, Veselic M et al. Endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of lung cancer and its impact on surgical staging. J. Clin. Oncol.23(33), 8357–8361 (2005).
   PubMed Web of Science ®Google Scholar
• Tournoy K, Praet M, Joos G, van Meerbeeck JP. EUS-FNA with on-site cytopathologist: high accuracy for the diagnosis of mediastinal lymphadenopathy. Chest128(4), 3004–3009 (2005).
   PubMedGoogle Scholar
• Detterbeck FC. Evolution and science, progress and change. Thorax62, 654–655 (2007).
   PubMedGoogle Scholar
• Gilligan D, Nicolson M, Smith I et al.; on behalf of the trial collaborators. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet369, 1929–1937 (2007).
   PubMed Web of Science ®Google Scholar
• Pisters K, Pisters K, Vallieres E; on behalf of Southwest Oncology Group. S9900: surgery alone or surgery plus induction (ind) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): follow-up on a Phase III trial. J. Clin. Oncol.25(Suppl. 18) 7520 (2007).
   Google Scholar
• Van Meerbeeck JP, Kramer G, Van Schil P et al. Induction chemotherapy (CT) in stage IIIA–N2 non-small cell lung cancer (NSCLC): an analysis of different regimens used in EORTC 08941. Lung Cancer41, S79–S80 (2003).
   Google Scholar
• Vokes EE, Herndon JE II, Crawford J et al. Randomized Phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and Leukemia Group B Study 9431. J. Clin. Oncol.20, 4191–4198 (2002).
   PubMed Web of Science ®Google Scholar
• Kelly K, Chansky K, Gaspar LE et al. Updated analysis of SWOG 0023: a randomized Phase III trial of gefitinib versus placebo maintenance after definitive chemoradiation followed by docetaxel in patients with locally advanced stage III non-small cell lung cancer. J. Clin. Oncol.25(Suppl. 18) 7513 (2007).
   Google Scholar
• Herbst R, Chansky K, Kelly K et al. A Phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced non-small cell lung cancer (NSCLC): final report of SWOG 0342. J. Clin. Oncol.25(Suppl. 18) 7545 (2007).
   Google Scholar
• Stewart LA, Burdett S, Tierney JF; on behalf of the NSCLC Collaborative Group. Surgery and adjuvant chemotherapy (CT) compared to surgery alone in non-small cell lung cancer (NSCLC): a meta-analysis using individual patient data (IPD) from randomized clinical trials (RCT). J. Clin. Oncol.25(Suppl. 18) 7552 (2007).
   Google Scholar
• Vokes Le Péchoux C, Tribodet H, Pignon JP; on behalf of the NSCLC Collaborative Group. Surgery (S) and radiotherapy (RT) plus adjuvant chemotherapy (CT) versus surgery and radiotherapy in non-small cell lung cancer (NSCLC): a meta-analysis using individual patient data (IPD) from randomised clinical trials (RCTs). J. Clin. Oncol.25(Suppl. 18) 7521 (2007).
   Google Scholar
• Gandara DR, Chansky K, Albain KS et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: Phase II Southwest Oncology Group Study S9504. J. Clin. Oncol.21, 2004–2010 (2003).
   PubMedGoogle Scholar
• Hanna NH, Neubauer M, Ansari R et al.. Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01–24/USO-023. J. Clin. Oncol.25(Suppl. 18) 7512 (2007).
   Google Scholar
• Aupérin A, Rolland E, Curran WJ et al.; on behalf of the NSCLC Collaborative Group. Concomitant radio-chemotherapy (RT–CT) versus sequential RT–CT in locally advanced non-small cell lung cancer (NSCLC): a meta-analysis using individual patient data (IPD) from randomised clinical trials (RCTs). J. Thorac. Oncol.2, S310 (2007).
   Web of Science ®Google Scholar
• Kim MK, Kim S, Choi E et al. Induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) versus CCRT alone for unresectable stage III non-small cell lung cancer (NSCLC): a randomized Phase III trial. J. Thorac. Oncol.2, S308 (2007).
   Google Scholar
• Thomas M, Macha HN, Ukena D et al. Cisplatin/etoposide (PE) followed by twice-daily chemoradiation versus PE alone before surgery in stage III non-small cell lung cancer. A randomized Phase III trial of the German Lung Cancer Cooperative Group (GLCCG). J. Clin. Oncol.22, 14S (2004).
   Google Scholar
• Belani CP, Wang W et al.; on behalf of Eastern Cooperative Oncology Group. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. J. Clin. Oncol.23(16), 3760–3767 (2005).
   PubMed Web of Science ®Google Scholar
• Graham MV, Purdy JA, Emami B et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int. J. Radiat. Oncol. Biol. Phys.45(2), 323–329 (1999).
   PubMed Web of Science ®Google Scholar
• Wei X, Liu HH, Tucker SL et al. Risk factors for acute esophagitis in non-small cell lung cancer patients treated with concurrent chemotherapy and three-dimensional conformal radiotherapy. Int. J. Radiat. Oncol. Biol. Phys.66, 100–107 (2006).
   PubMed Web of Science ®Google Scholar
• Yuan S, Yu J, Sun X et al. Three dimensional conformal involved-field RT for stage III NSCLC.J. Clin. Oncol.24(Suppl.), 7044 (2006).
   Google Scholar
• Yom SS, Liao Z, Liu HH et al. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int. J. Radiat. Oncol. Biol. Phys.68(1), 94–102 (2007).
   PubMed Web of Science ®Google Scholar
• De Ruysscher D, Wanders S, van Haren E et al. Selective mediastinal node irradiation based on FDG-PET scan data in patients with nonsmall-cell lung cancer: a prospective clinical study. Int. J. Radiat. Oncol. Biol. Phys.62, 988–994 (2005).
   PubMed Web of Science ®Google Scholar
• Piet AH, Lagerwaard FJ, Kunst PW et al. Can mediastinal nodal mobility explain the low yield rates for transbronchial needle aspiration without real-time imaging? Chest131(6), 1783–1787 (2007).
   PubMedGoogle Scholar
• Underberg RW, van Sörnsen de Koste JR, Lagerwaard FJ et al. A dosimetric analysis of respiration-gated radiotherapy in patients with stage III lung cancer.Radiat. Oncol.1, 8 (2006).
   PubMed Web of Science ®Google Scholar
• Cox JD, Chang J, Liao Z. Acute esophageal reactions from proton beam therapy and concurrent chemotherapy for non-small cell lung cancer (NSCLC): reduction in incidence and severity despite higher doses. J. Thorac. Oncol.2, S449 (2007).
   Google Scholar